Hospital emergency departments (EDs) are sites where the majority of patients with serious, acute bacterial infections initially seek medical care. As such, these sites often represent the initial treatment setting, where patients receive the first dose of antibiotic(s) and are triaged for possible hospital admission or subsequent therapy in the outpatient setting. Therefore, EDs play an important role in initial treatment/brand selection. This report examines the current trends in management and antibiotic treatment of patients presenting to EDs with bacterial infections, and it examines their management and treatment through hospital inpatient and/or outpatient care following discharge. The report evaluates prescribing practices and guidelines in the ER, in the inpatient setting, and upon patient discharge.
Questions Answered in This Report:
- Explore the implementation of antibiotic treatment guidelines for the ED and inpatient wards, admissions policies and prevalence of hospitalization avoidance programs, and the burden of readmissions due to bacterial infections.
- Evaluate the flow of patients requiring antibiotic therapy through the hospital after presentation at the ED and determine treatment practices, hospital and discharge prescribing, and continuum of care through treatment settings.
- Understand empiric prescribing for suspected MRSA and GN infections in the hospital, including ED and hospital inpatient use of agents.
- Determine OPAT prescribing for ED and hospital discharge patients by infection type and product, and reveal key drivers and obstacles to wider use of this treatment modality.
- Identify key product attributes that drive physicians’ prescribing decisions, and evaluate the performance of current products on those attributes.
- Evaluate unmet need and anticipated changes in future antibiotic prescribing and physician willingness to prescribe key emerging therapies.
Markets covered: United States.
Primary research: 104 prescribers: 54 emergency department physicians, 12 infectious disease specialists, 15 critical care/intensive care unit specialists, 13 internists, and 10 hospitalists.
Indication coverage: Gram-negative and methicillin-resistant Staphylococcus aureus (MRSA) infections.
Mladen Tomich, Ph.D.